Microfluidic Hemostasis Assay for Rapid Drug Level Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Traditional systems struggle to accurately assess bleeding and clotting risk in emergency critical care environments by failing to mimic human blood clotting physiology, provide specific data on key components of hemostasis, and deliver results in a timely manner.
Innovation Solution
A system comprising a microfluidic device, reagents, imaging instrument, and software that measures platelet and fibrin signals to determine the presence and concentration of drugs affecting hemostasis, using a method that mimics blood flow and coagulation processes, allowing for real-time analysis of platelet and coagulation function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional testing systems are used to assess bleeding and clotting risk, then the testing process is simple, but the system cannot create a testing environment analogous to human blood clotting physiology and cannot provide specific data on platelets and coagulation
Solution Approach 1:
The system segments the hemostasis assessment into distinct measurable components: platelet accumulation (measured by platelet-specific fluorescent label) and fibrin formation (measured by fibrinogen-specific fluorescent label). This segmentation allows specific data on each key component to be obtained independently while maintaining a manageable system architecture through modular detection channels.
Solution Approach 2:
The system uses fluorescent labels as intermediaries to detect platelet and fibrin accumulation. The platelet-specific fluorescent label and fibrinogen-specific fluorescent label act as mediators that bind to their respective targets and emit detectable signals, enabling precise measurement without direct manipulation of the blood components themselves.
2Productivity
If traditional systems are used for hemostasis assessment, then the system structure is simple, but results cannot be provided in the timeframe required for critical care decision making
Solution Approach 1:
The system replaces traditional mechanical/chemical clotting assessment methods with optical detection using fluorescent labels. This substitution enables real-time, non-invasive monitoring of platelet and fibrin accumulation through light emission, providing rapid results without the time-consuming procedures of conventional hemostasis testing while maintaining measurement precision.
Solution Approach 2:
The microfluidic device enables continuous flow of blood through the reaction zones, allowing uninterrupted real-time monitoring of clot formation. The continuous fluorescent signal detection provides ongoing data on platelet and fibrin accumulation rates, enabling rapid assessment within the critical decision-making timeframe without interrupting the hemostatic process.
3Loss of information
If a system measures both platelet and fibrin signals simultaneously, then comprehensive hemostasis data is obtained, but the device complexity increases
Solution Approach 1:
The system merges platelet detection and fibrin detection into a single integrated microfluidic device with unified blood flow path. Both platelet-specific and fibrinogen-specific fluorescent labels are introduced into the same blood sample and detected simultaneously through coordinated optical channels, obtaining comprehensive hemostasis data from one test while avoiding the need for separate testing systems.
Solution Approach 2:
The microfluidic device performs multiple functions: it simultaneously measures platelet accumulation, fibrin formation, and their interaction in a single integrated platform. The reaction zones are designed to support concurrent detection of multiple hemostatic parameters, making the device universally applicable for comprehensive hemostasis assessment rather than requiring specialized separate devices for each measurement.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables accurate and timely determination of a patient's hemostatic state, identifying drug presence and concentration, thereby improving critical care decision-making by providing detailed information on bleeding and clotting risks.
Implementation Method 1
using a method that mimics blood flow and coagulation processes
Implementation Method 2
coagulation involving a system of enzymatic reactions that generate thrombin and fibrin that stabilize the clot
Implementation Method 3
hemostasis involving a physiological response to vessel damage to arrest blood leakage involving both platelet aggregation and coagulation
Data Source
AI summary
An example system for detecting and quantifying drug and/or chemical interactions with a biological sample is provided. The system includes a detection instrument with computing capability. The system includes an assay device capable of receiving a biological sample. Introduction of the biological sample into the assay device results in a biological process by which fibrin and platelets may accumulate at a reaction zone of the assay device. The assay device is capable of receiving one or more chemical reagents and one or more drug reagents. The fibrin and platelets, and their associated signals, accumulated at the reaction zone of the assay device are usable to determine at least one of a drug presence, a drug class, a drug level in relation to a threshold, or a drug concentration, within the biological sample.